National Institute for Public Health and the Environment
The aim of Protocol ALL-10 is to improve the overall treatment results in terms of EFS and to decrease treatment intensity in patients with a pEFS of >95%. Therapy will be tailored according to the risk of relapse as determined by the MRD levels at 2 time points during the first months of therapy. This tailored therapy should lead to less intensive therapy for patients with low risk of relapse and to intensification of therapy for patients with medium and high risk of relapse.
Protocol ALL 10, protocol voor diagnostiek en behandeling van kinderen en adolescenten (1-19 jaar) met Acute Lymfatische Leukemie (ALL)
Acute Lymfatische Leukemie
1. To improve the overall outcome as compared to the previous protocols of the DCOG, especially ALL-9 and ALL-10. This is aimed for by decreasing therapy for part of the patients (TEL/AML1, Down syndrome, PPR only), increasing therapy for IKZF1 mutated cases, decreasing the cumulative dose of anthracyclines, omitting cranial irradiation and total body irradiation and individualizing asparaginase therapy for all patients. 2. Does a continuous schedule of Asparaginase lead to less allergic reaction/inactivation of Asparaginase than the standard non continuous schedule of Asparaginase? Patients are randomized to receive noncontinuous PEGasparaginase in IA (induction) and intensification of the Medium Risk group (standard arm A) or to receive continuous PEGasparaginase in IA, IB, M and intensification (continuous arm B) with the same cumulative number of doses of PEGasparaginase. 3. Does prophylactic administration of intravenous immunoglobulins reduce the number of infections during the intensive treatment phases? Patients are randomized in the induction and MR treatment group to receive or not receive prophylactic immunoglobulins. 4. Individualize the dose schedule of asparaginase by therapeutic drug monitoring in order to detect silent inactivation of asparaginase, to prevent allergic/anaphylactic reactions, to switch Asparaginase preparation in time and to prevent too high levels with possible toxicity.
PROTOCOL ALL 11: Treatment study protocol of the Dutch Childhood Oncology Group for Children and adolescents (1-19 year) with newly diagnosed acute lymphoblastic leukemia
The Athero-Express Biobank Study (AE) and the Abdominal Aortic Aneurysm-Express Biobank Study (AAA) are two ongoing, prospective biobank studies initiated in 2002 and 2003, respectively. Together, they comprise detailed histological and clinical data from over 4,500 patients who underwent arterial surgery at two Dutch tertiary referral centers. The AE Biobank includes over 3,500 patients who underwent endarterectomy to remove atherosclerotic plaques, predominantly from the carotid and femoral arteries. The AAA Biobank includes over 1,000 patients who underwent open surgical repair of arterial aneurysms, primarily abdominal aortic aneurysms. For both studies, blood and vascular tissue (plaque or aneurysm wall) were collected during surgery and stored at −80℃. Tissue material is routinely processed for standardised (immuno)histochemical analysis, with histological observations performed by the same dedicated technician, ensuring consistency; interobserver analyses have been previously reported. In AE, the following plaque characteristics were quantified or scored: • Macrophages (CD68) and smooth muscle cells (α-actin) as the percentage of field area using computerised analysis. • Intraplaque vessel density (CD34) as the average count per 3 hotspots. • Intraplaque haemorrhage (IPH) was scored as absent/present using hematoxylin and eosin (HE). • Intraplaque fat was defined as < or ≥40% of total plaque area (HE). • Calcification (HE) and collagen content (picrosirius red) were scored as no/minor vs. moderate/heavy staining. • Overall plaque vulnerability was assessed following the method by Verhoeven et al. In AAA, tissue sections were stained using: • HE, EVG (elastin), picrosirius red (collagen), SMA (smooth muscle cells), CD68 (macrophages), CD3 (T cells), CD20 (B cells), CD138 (plasma cells), and von Willebrand factor (vasa vasorum). • Each marker was semiquantitatively scored from 0 to 3 (0: none, 1: minor, 2: moderate, 3: heavy), separately for the intima, media, and adventitia, across both structural components and immune cell types. For both cohorts, clinical data is obtained through standardised questionnaires, and supplemented with electronic health records where necessary. Ethical approval for this study (TME/C-01.18) was provided by the Medical Research Ethics Committee of University Medical Center Utrecht, Utrecht, The Netherlands on 10 April 2002, and all research was conducted according to the principles of the Declaration of Helsinki (59th amendment, Seoul 2008) and in accordance with the Dutch Medical Research Involving Human Subjects Act (WMO).
The Athero-Express Biobank Study (AE) is a longitudinal cross-sectional biobank study collecting blood and atherosclerotic plaque samples from patients undergoing endarterectomy. Clinical data is collected through standardised questionnaires and supplemented by querying electronic health records when needed. Patients are followed up to 3 years after surgery.
Athero- and Aneurysm-Express Biobank Studies
aneurysm
arterial endarterectomy
atherosclerosis
plaque
The BioDay registry is a disease or condition registry for atopic dermatitis (AD)/prurigo nodularis (PN). All patients treated with advanced systemic therapy (biologics and JAK inhibitors [JAKi]) for AD are eligible for inclusion in the prospective, multicenter, observational BioDay registry. Patients are treated in a daily practice setting and the choice of treatment is determined by shared decision making and according to the Dutch AD guidelines. During all visits both clinical outcomes (e.g. EASI, IGA) and patient reported outcomes (e.g. NRS itch, DLQI,ADCT/RECAP) are collected.
Multicenter prospective observational atopic dermatitis registry
BioDay Registry
JAK inhibitors
abrocitinib
atopic comorbidities
atopic dermatitis
baricitinib
biologicals
daily practice
dupilumab
lebrikizumab
multicenter
prurigo nodularis
real-world evidence
registry
tralokinumab
upadacitinib
EPIC is the European Prospective Investigation Into Cancer and Nutrition. EPIC-NL is the Dutch contribution to EPIC and comprises about 40,000 individuals prospectively followed since the early 90's. Biological samples have been stored in liquid nitrogen and repeated follow-up of the cohort has occured to obtain detailed information on lifestyle and behavioural factors and morbidity and mortality.
At baseline, the prevalence of risk factors for chronic diseases was determined using self-administered questionnaires and a physical examination. Participants are followed up over time for changes in exposure and for the occurrence of cancer, diabetes, cardiovascular diseases, and other medical conditions. Subgroups of participants were invited for several follow-up rounds.
European Prospective Investigation Into Cancer and Nutrition in the Netherlands (EPIC-NL)
bloodsamples
cancer
cardiovascular disease
cause of death
chronic disease
diabetes
environmental exposure
lifestyle
morbidity
mortality
nutrition
In this single center retrospective cohort study, regular care data of total knee arthroplasty and total hip arthroplasty was extracted from medical records of people with bleeding disorders who attended the Van Creveldkliniek, University Medical Center Utrecht, between 1989 and 2025. Patients with moderate or severe haemophilia A or B (FVIII/FIX <5%) or Von Willebrand’s disease (VWD) with a FVIII activity <5% were included. All types of primary THA or TKA were included. All patients were followed according to standard care. The primary outcome was time to prosthesis failure, defined as revision or indication for revision (but patients are inoperable or refuse), measured in years.
Single center retrospective cohort study,
Long-term prosthesis survival of total hip and total knee arthroplasty in people with inherited bleeding disorders
haemophilia
joint arthroplasty
survival
total hip
total knee
The Julius General Practitioners Network (JHN) is a database of primary care routine data. It is a network of approximately seventy general practices with two hundred general practitioners and over 450,000 active patients in the Utrecht area. The database contains data on more than 1.5 million patients from 1995 to the present.
Electronic Health Recors of Patients in Primary Care
Julius Huisartsen Netwerk
Electronic Health Record
General Practitioner
Primary Care
MARS is a multicenter prospective cohort of ICU patients aimed at developing new molecular technologies for early diagnosis and risk stratification of sepsis. MARS contains comprehensive clinical data (including admission diagnoses, comorbidities, daily treatments, medications, vital-signs, labs, and microbiology results). In addition, daily prospective adjudication of infection plausibility was performed, according to standardized definitions.
Ongoing prospective cohort and biobank of ICU patients admitted to the UMC Utrecht since 2011. The AMC was a participating center between 2011 and 2013.
MARS - Molecular Diagnosis and Risk Stratification of Sepsis
Biobank
Biomarkers
Blood samples
Citrate
Clinical
Cohort
EDTA
Heparin
ICU
Infections
Intensive Care
Pathogen detection
Plasma
Pneumonia
Prospective
Vital signs
Inflammatory Bowel Diseases (IBD), i.e. Crohn’s Disease (CD) and Ulcerative Colitis (UC), are thought to arise in genetically susceptible individuals in the context of environmental triggers, with a potential dominant role for the interplay between the gut microbiota, and the mucosal immune system. However, the relative importance and the exact role of these factors in the pathogenesis of IBD is presently unknown. Interpretation of published research in this field is often hampered by reverse causation, and data generated in animal models cannot be directly extrapolated to the human condition. The disease is probably triggered years before the occurrence of symptoms, but currently patients are only identified when clinical disease is established. The preclinical phase of IBD might hold the key to understanding the pathogenesis of IBD and could provide a huge window of opportunity of halting or even preventing disease development. At this time, data on this phase of the disease are limited. Identifying and validating biomarkers and pathophysiological mechanisms is one of the necessary steps toward prediction, prevention and optimalization of therapy in IBD care. Unaffected twin-siblings of IBD affected individuals are at increased risk of developing IBD. Therefore, studying IBD-discordant, IBD-concordant and non-IBD-concordant twins or multiples gives the unique opportunity to 1) define mechanisms that underlie (the early development of) IBD and 2) identify and validate markers of (pre)clinical IBD.
Observational study with both a cross-sectional and longitudinal design
Twin cohort for the study of (pre)clinical Inflammatory Bowel Disease in the Netherlands: The TWIN-study
Crohn s disease
cohort
concordance
ibd
twin
twins
ulcerative colitis
The prospective, multicenter ‘Utrecht cohort for Multiple BREast cancer intervention studies and Long-term evaluAtion’ (UMBRELLA) cohort, established in 2013, serves as an infrastructure for conducting randomized controlled trials to evaluate effectiveness of (innovative) cancer treatments and survivorship care for breast cancer patients and survivors. UMBRELLA includes patients with histologically proven invasive breast cancer or ductal carcinoma in situ (DCIS) referred for breast cancer treatment in multiple hospitals in the Netherlands. All UMBRELLA cohort participants consent for the collection and use of their clinical data. In addition, cohort participants can also provide consent for the longitudinal collection and use of patient-reported outcomes up to 10 years after enrolment. Last, cohort participants are also asked to provide consent to be randomized into future cohort-based trials following the Trial within Cohorts design. When conducting a cohort-based trial, all UMBRELLA cohort participants are screened for eligibility. Cohort participants assigned to the intervention arm, are offered the intervention, whereas cohort participants assigned to the control arm are not informed about the intervention and remain unaware of the trial. By combining clinical data with (long-term) patient-reported outcomes from a large prospective cohort of breast cancer patients and survivors, it is possible to effectively study a diversity of clinically relevant questions to gain further insights in the effects of breast cancer treatment and its impact on quality of life as well as to evaluate effectiveness of interventions within the breast cancer field.
All UMBRELLA cohort participants consent for the collection and use of their clinical data. In addition, cohort participants can also provide consent for the longitudinal collection and use of patient-reported outcomes up to 10 years after enrolment. Last, cohort participants are also asked to provide consent to be randomized into future cohort-based trials following the Trial within Cohorts design. When conducting a cohort-based trial, all UMBRELLA cohort participants are screened for eligibility. Cohort participants assigned to the intervention arm, are offered the intervention, whereas cohort participants assigned to the control arm are not informed about the intervention and remain unaware of the trial.
'Utrecht cohort for Multiple BReast cancer intErvention studies and Long-term evaluation' cohort
Breast cancer prospective cohort multicenter quality of life
The VIOOL study is a prospective observational cohort conducted across three winter seasons (2021–2024; October–April/May) in the Netherlands. Children under 4 years of age were recruited from the community and followed for 16 weeks. Parents recorded daily symptom diaries and collected weekly nasal swabs, regardless of symptoms. Swabs were analyzed by PCR for a broad panel of common respiratory viruses. Its primary objective is to examine interactions between respiratory virus infections in young children. The study was approved by the Medical Ethics Committee of the University Medical Centre Utrecht (UMCU) and registered in the Clinical Trials Register (NL78424.041.21).
Virus Interactions in the Respiratory Tract; a Cohort Study With Children (VIOOL)
acute respiratory illness
coinfections
healthy children
population cohort
respiratory viruses
viral interactions
Data collection of the Amsterdam Dementia Cohort started in 2010 and is ongoing. All study participants undergo a standardized screening protocol for dementia. This dataset includes data on neuropsychological assessment.
Amsterdam Dementia Cohort - Neuropsychological Assessment
MRI
Alzheimer
Dementia
EEG
Imaging
MEG
Neurophysiology
Nederlands Kanker Instituut - Antoni van Leeuwenhoekziekenhuis
Hebon, initiated by NKI-AVL in 1997, is an active multidisciplinary collaboration of Clinical Genetics and laboratory departments of all University Medical Centers in the Netherlands and the Netherlands Cancer Institute, conducting a dynamic prospective cohort study for members of breast and ovarian cancer families. Currently 60,000 persons are enrolled. Hebon collects DNA test outcome results, self-reported risk factor data via questionnaires, pedigree data, mammography and MRI data, treatment data through linkage with the Netherlands Cancer Registry and Palga, vital status through linkage with the Dutch municipality register (BRP) and cause of death data via linkage with the Dutch Central Bureau of Statistics.
The nationwide HEreditary Breast and Ovarian cancer study the Netherlands (Hebon)
Breast Cancer
Cancer Genetics
Epidemiology
Hereditary Breast and Ovarian Cancer
Ovarian Cancer
Amsterdam Dementia Cohort - Biomarkers
Data collection of the ABOARD Cohort started in 2022 and is ongoing. Participants receive annual online questionnaires on (mental) health, quality of life, and use of healthcare resources. In addition, medical data is collected from participants that visited a physician because of (self-reported) memory problems.
ABOARD Cohort
PROMS
Background The faecal immunochemical test (FIT) is widely employed for colorectal cancer screening. However, its sensitivity for advanced precursor lesions remains suboptimal. The multitarget FIT (mtFIT), measuring haemoglobin, calprotectin, and serpin family F member 2, has demonstrated enhanced sensitivity for advanced neoplasia, especially advanced adenomas, at equal specificity to FIT. This study aimed to prospectively validate and investigate the clinical utlitity of mtFIT versus FIT in a setting of population-based colorectal cancer screening. Methods Individuals aged 55–75 years and who were eligible for the Dutch national FIT-based colorectal cancer screening programme were invited to submit both a FIT and mtFIT sample collected from the same bowel movement. Positive FIT (47 μg/g haemoglobin cutoff) or mtFIT (based on decision-tree algorithm) led to a colonoscopy referral. The primary outcome was the relative detection rate of mtFIT versus FIT for all advanced neoplasia. Secondary outcomes were the relative detection rates of colorectal cancer, advanced adenoma, and advanced serrated polyps individually and the long-term effect of mtFIT-based versus FIT-based programmatic screening on colorectal cancer incidence, mortality, and cost, determined with microsimulation modelling. The study has been registered in ClinicalTrials.gov, NCT05314309, and is complete. Findings Between March 25 and Dec 7, 2022, 35786 individuals were invited to participate in the study, of whom 15283 (42·7%) consented, and 13187 (86·3%) of 15283 provided both mtFIT and FIT samples with valid results. Of the 13187 participants, 6637 (50·3%) were male and 6550 (49·7%) were female. mtFIT showed a 9·11% (95% CI 8·62–9·61) positivity rate and 2·27% (95% CI 2·02–2·54) detection rate for advanced neoplasia, compared with a positivity rate of 4·08% (3·75–4·43) and a detection rate of 1·21% (1·03–1·41) for FIT. Detection rates of mtFIT versus FIT were 0·20% (95% CI 0·13–0·29) versus 0·17% (0·11–0·27) for colorectal cancer; 1·64% (1·43–1·87) versus 0·86% (0·72–1·04) for advanced adenoma, and 0·43% (0·33–0·56) versus 0·17% (0·11–0·26) for advanced serrated polyps. Modelling demonstrated that mtFIT-based screening could reduce colorectal cancer incidence by 21% and associated mortality by 18% compared with the current Dutch colorectal cancer screening programme, at feasible costs. Furthermore, at equal positivity rates, mtFIT outperformed FIT in terms of diagnostic yield. At an equally low positivity rate, mtFIT-based screening was predicted to further decrease colorectal cancer incidence by 5% and associated mortality by 4% compared with FIT-based screening. Interpretation The higher detection rate of mtFIT for advanced adenoma compared with FIT holds the potential to translate into additional and clinically meaningful long-term colorectal cancer incidence and associated mortality reductions in programmatic colorectal cancer screening. Funding Stand Up to Cancer, Dutch Cancer Society, Dutch Digestive Foundation, and Health~Holland.
The multitarget faecal immunochemical test for improving stool-based colorectal cancer screening programmes: a Dutch population-based, paired-design, intervention study
Adenoma
Colorectal Neoplasms
Defecation
Early Detection of Cancer
Hemoglobins
Humans
Purpose: Circulating tumor DNA (ctDNA) has the potential to guide therapy selection and monitor treatment response in patients with metastatic cancer. However, germline and clonal hematopoiesis–associated alterations can confound identification of tumor-specific mutations in cell-free DNA (cfDNA), often requiring additional sequencing of tumor tissue. The current study assessed whether ctDNA-based treatment response monitoring could be performed in a tumor tissue–independent manner by combining ultra-deep targeted sequencing analyses of cfDNA with patient-matched white blood cell (WBC)-derived DNA. Experimental Design: In total, 183 cfDNA and 49 WBC samples, along with 28 tissue samples, from 52 patients with metastatic colorectal cancer participating in the prospective phase III CAIRO5 clinical trial were analyzed using an ultra-deep targeted sequencing liquid biopsy assay. Results: The combined cfDNA and WBC analysis prevented false-positives due to germline or hematopoietic variants in 40% of patients. Patient-matched tumor tissue sequencing did not provide additional information. Longitudinal analyses of ctDNA were more predictive of overall survival than standard-of-care radiological response evaluation. ctDNA mutations related to primary or acquired resistance to panitumumab were identified in 42% of patients. Conclusions: Accurate calling of ctDNA mutations for treatment response monitoring is feasible in a tumor tissue–independent manner by combined cfDNA and patient-matched WBC genomic DNA analysis. This tissue biopsy-independent approach simplifies sample logistics and facilitates the application of liquid biopsy ctDNA testing for evaluation of emerging therapy resistance, opening new avenues for early adaptation of treatment regimens.
Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
Cell-Free Nucleic Acids
Circulating Tumor DNA
Colonic Neoplasms
High-Throughput Nucleotide Sequencing
Mutation
Neoplasm DNA
Prospective Studies
Rectal Neoplasms
Tumor Biomarkers
Data collection of the Amsterdam Dementia Cohort started in 2010 and is ongoing. All study participants undergo a standardized screening protocol for dementia. This dataset includes data on neuroimaging-and neurophysiology data including MRI, EEG, and MEG.
Amsterdam Dementia Cohort - Neuroimaging & Neurophysiology
The Amsterdam Dementia Cohort was established in 2000, along with the foundation of the VU University Medical Center (VUmc) Alzheimer Center in the Netherlands. All patients that visit the Alzheimer Center are asked to consent to the use of their clinical data for scientific purposes. This population of patients comprises the Amsterdam Dementia Cohort, which consisted of almost 8,000 patients as of the 1st of January, 2021. After a baseline visit, the majority of patients visit the clinic annually for follow-up.
Amsterdam Dementia Biobank
Samples
Data collection of the Amsterdam Dementia Cohort started in 2010 and is ongoing. All study participants undergo a standardized screening protocol for dementia. This dataset includes data on demographics and neurological-and physical examination.
Amsterdam Dementia Cohort - Demographics & Neurological/Physical Examination
Demographics
Health-RI cBioPortal: CAIRO5 (Clinical Cancer Res 2023)
EGA: Tissue DNA, WBC DNA and cfDNA (deep-)sequencing of mCRC patients treated with doublet chemotherapy and anti-EGFR in the CAIRO5 study.
HEreditary Breast and Ovarian cancer study the Netherlands (Hebon)
mtFIT, Lancet Oncol 2024 codebook
Health-RI cBioPortal: mtFIT (Lancet Oncol 2024)
CAIRO5, Clin Cancer Res 2023 codebook
collection type: Disease specific,Hospital,Sample collection | disease: ICD 125* Chronic Coronary Disease | data categories: Biological samples,Imaging data,Medical records | materials: Serum | omics: Proteomics | imaging: Y | sex: Female,Male
Double blind randomised clinical trial with colchicin/ placebo in patients with chronic coronary disease. 5552 Pts in Netherlands and Australia
Colchicin in patients with chronic coronary disease
Biological samples
Disease specific
Female
Hospital
ICD 125 Chronic Coronary Disease
Imaging data
LoDoCo2
Male
Medical records
Proteomics
Sample collection
Serum
collection type: Other | disease: Sudden cardiac death, so described | data categories: Physiological/Biochemical measurements | materials: Not available | omics: Not available | imaging: N | sex: Female,Male
We propose a new treatment methodology that 1) is able to predict an upcoming ventricular tachy-arrhythmic event and 2) can initiate a preventive intervention. This methodology can be built into an ICD and uses beat-to-beat variability of repolarization quantified as short-term variability (STV) to continuously monitor the repolarization reserve of the heart. When a ventricular arrhythmia is forthcoming, this algorithm can activate the ICD to temporarily pace the heart at a higher frequency, thereby restoring/improving the repolarization strength of the heart and preventing the arrhythmia from occurring.
Continuous monitoring of short-term variability of repolarization for prediction and prevention of ventricular arrhythmias and sudden cardiac death.
Not available
Other
Physiological Biochemical measurements
STV 24 7
Sudden cardiac death
so described
collection type: Other | disease: Ischaemic heart diseases,Atrial fibrillation and flutter,Other cardiac arrhythmias | data categories: Other | materials: Not available | omics: Other | imaging: Y | sex: Female,Male
CVON-AI, is a consortium involving 12 partners, established with the support of 5 previously established CVON consortia, all working with big-data. The project will build a generic AI cloud-platform to catalyse the application of AI by Dutch scientists to find novel solutions to questions in the already existing CVON consortia
CVON-AI - Catalysing the application of Artificial Intelligence for Cardiovascular Research Netherlands
Atrial fibrillation and flutter
CVON-AI
Ischaemic heart diseases
Other cardiac arrhythmias
collection type: Case-Control,Cohort,Cross-sectional,Image collection | disease: Atherosclerotic heart disease | data categories: Imaging data,Medical records | materials: Not available | omics: Not available | imaging: Y | sex: Female
In CREW we addressed the following topics: - The prevalence of (subclinical) CVD in middle-aged women with PCOS/POI - The prevalence of (subclinical) CVD in middle-aged women with a history of PE - Migraine as determinant of stroke risk during reproductive age - VTE-risk during reproductive age
Dutch national consortium to promote cardiovascular healthy ageing in women
Atherosclerotic heart disease
CREW
Case-Control
Cross-sectional
Image collection
Volwassenen van 18 jaar of ouder die een eerste atriumfibrilleren of atriumflutter diagnose hebben gekregen.
De Atriumfibrilleren registratie omvat patiënten met de novo atriumfibrilleren en/of atriumflutter. Het betreft patiënten (18 jaar of ouder) met een eerste AF / atriumflutter diagnose, geregistreerd op een 12-kanaals ECG, een holteronderzoek (minstens 30 seconden durend) of device detected. Indien device detected dan geldt een atrial high-rate episode (AHRE) > 24u durend als inclusiecriterium.
Atriumfibrilleren registratie
atrial fibrillation
atrial flutter
cardiac rhythm
heart
quality registry
Patiënten (kinderen en volwassenen) die een device en/of lead ingreep hebben ondergaan.
De pacemaker- en ICD registratie omvat alle ingrepen tijdens een interventie gerelateerd aan een pacemaker, ICD, implanteerbare hartmonitor (ICM) en/of bijbehorende lead(s). Het gaat hierbij om zowel implantaties, vervangingen en explantaties, als andere type ingrepen, zoals afgebroken ingrepen en reposities.
Pacemaker- en ICD registratie
AV-block
CRT
ICD
ICM
device
heart failure
leads
pace and ablate
pacemaker
sick sinus syndrome
transvenous
collection type: Other | data categories: Not available | materials: Other | omics: Proteomics | imaging: N | sex: Not asked
DCVA sample collection Outflow tract related aging with congenital heart defects: identifying causes and mechanisms of myocardial and large vessel wall adaptation, predictors for long term outcome and targets for improved treatment.
Outflow tract related aging with congenital heart defects: identifying causes and mechanisms of myocardial and large vessel wall adaptation, predictors for long term outcome and targets for improved treatment.
Not asked
OUTREACH WP6
collection type: Cohort,Disease specific,Hospital | data categories: Medical records,National registries,Physiological/Biochemical measurements,Survey data | materials: Not available | omics: Not available | imaging: N | sex: Female,Male
CAPACITY is a registry of patients with COVID-19 across Europe and has been established to answer questions on the role of cardiovascular disease in this pandemic. It is an extension of the Case Record Form (CRF) that was released by the ISARIC (International Severe Acute Respiratory and Emerging Infection Consortium) and WHO (World Health Organisation) in response to the emerging outbreak of COVID-19.The aim of CAPACITY is to collect data regarding the cardiovascular history, diagnostic information and occurrence of cardiovascular complications in COVID-19 patients. By collecting this information in a standardized manner, CAPACITY can aid in providing more insight in (1) the incidence of cardiovascular complications in patients with COVID-19, and (2) the vulnerability and clinical course of COVID-19 in patients with an underlying cardiovascular disease
CAPACITY-COVID
National registries
Survey data
collection type: Cohort,Disease specific,Hospital,Non-Human,Sample collection | disease: Other conduction disorders | data categories: Biological samples,Imaging data,Medical records,Physiological/Biochemical measurements,Other | materials: cDNA / mRNA,Cell lines,DNA,Serum,Tissue, cryo preserved | omics: Proteomics | imaging: N | sex: Female,Male
Atrial fibrillation (AF) is the most common age-related cardiac rhythm disorder accounting for about one-third of rhythm abnormalities related hospitalizations with annual costs in the European Union of 13 billion euro. Early recognition of AF is essential for prevention of disease progression from recurrent intermittent episodes to finally permanent AF. This progression is accompanied by a gradual increase in therapy failure and can in the end-stage even with extensive therapy not be treated. Persistence of AF is rooted in the presence of electropathology, which is defined as complex electrical conduction disorders caused by structural damage of atrial tissue. Therefore, early recognition of AF susceptibility in patients is of prime importance to halt electropathology and hence disease onset and progression. At present, AF can only be diagnosed with a surface electrocardiogram when a patient already suffers from AF. In addition, this rhythm registration cannot assess the degree of electropathology and thus the stage of AF which is essential for selection of the appropriate therapy. Hence, early recognition of AF and the start of effective treatment is seriously hampered. By exploiting electropathology, we are able to develop a novel diagnostic instrument to predict AF onset and early progression. We hypothesize that every patient has a unique biological and electrical signal profile that is influenced by age, gender and heart disease. This bio-electrical profile is deduced from the ratio abnormal/normal electrical signals in the atria and determination of specific biomarkers levels in tissue or blood samples related to structural damage. These outcomes are summarized in an AF Fingerprint. The primary objective of this project is to design a patient-specific invasive and non-invasive AF Fingerprint, which reveals the degree of electropathology and can be used to early recognize AF onset or progression in daily clinical practice. Hereto we utilize a bottom-up study design consisting of 3 different phases; AF Fingerprinting during longstanding persistent AF, progression from recurrent intermittent to persistent AF and early recognition of AF onset in a broad population. In order to achieve this we aim to 1) develop signal processing algorithms for automatic assessment of electrical profiles by quantifying signal features, 2) establish the effects of patient characteristics, different stages of AF on invasive electrical signal profiles by utilizing a unique high density atrial mapping approach (golden standard measurements) during cardiac surgery and non-invasive electrical signal profiles consisting of whole-heart body surface electrocardiograms, 3) construct AF Fingerprints, by correlating electrical signal profiles with levels of specific biomarkers related to structural damage in atrial tissue (invasive AF Fingerprint) and blood-based biomarkers (non-invasive AF Fingerprint) 4) design a mapping device for signal acquisition, compatible with the developed algorithmic software, for general use in clinical practice, replacing current available prototypes restricted by a limited number of electrode positions. At the end of this project, AF Fingerprinting can be used in daily clinical practice for early recognition or progression of AF by determination of stage of electropathology. As such, AF Fingerprinting enables early and optimal patient tailored AF treatment, thereby improving patient's outcome.
Atrial Fibrillation Fingerprinting
AFFIP
Cell lines
DNA
Non-Human
Other conduction disorders
Tissue
cDNA mRNA
cryo preserved
collection type: Hospital | disease: coronary artery disease | data categories: Medical records,National registries,Survey data,Other | imaging: Y | sex: Undifferentiated
CARRIER proposes a big data-driven approach to detection and prevention of coronary artery disease. Models learnt from big data will help identify patients at increased risk and will drive disease management. An electronic lifestyle coach will support adherence to a personalised health management plan co-created by patients and clinicians.
Coronary ARtery disease: Risk estimations and Interventions for prevention and EaRly detection
CARRIER
Undifferentiated
coronary artery disease
collection type: Cohort | disease: Other cerebrovascular diseases - Cerebral aneurysm, nonruptured | data categories: Imaging data,Medical records | materials: Not available | omics: Genomics | imaging: Y | sex: Female,Male
ERASE will deliver: 1. Knowledge if we should also offer screening for intracranial aneurysms (IA) to persons 1. who have a positive family history with first degree relatives with unruptured IA and 2. ≥35 yr who smoke(d) and have hypertension. 3. Genetic, clinical and anatomical risk factors that will contribute to the ability to predict persons at risk for IAs.
Optimal Early Recognition of persons at high risk of Aneurysmal Subarachnoid hemorrhagE
ERASE
Genomics
Other cerebrovascular diseases - Cerebral aneurysm
nonruptured
collection type: Population-based | data categories: Imaging data,Medical records,Physiological/Biochemical measurements,Other | materials: Not available | omics: Not available | imaging: Y | sex: Female,Male
Developing AI for ECG interpretation
ECG-AI
Population-based
collection type: Non-Human
DCVA sample collection Renal connection to microvascular disease and heart failure with preserved ejection fraction: the next phase
Renal connection to microvascular disease and heart failure with preserved ejection fraction: the next phase
RECONNEXT non-clinical part
collection type: Population-based | data categories: Biological samples,Medical records,National registries,Physiological/Biochemical measurements,Survey data,Other | sex: Undifferentiated
Smoking and insufficient physical activity are key risk factors for cardiovascular disease. Perfect Fit uses big data science techniques to develop highly personalized and adaptive virtual coaching for individuals at risk of cardiovascular disease. This will help them to live healthily and prevent disease.
Perfect Fit: Targeting key risk factors for cardiovascular disease in at-risk individuals using a personalized and adaptive approach
Perfect fit
collection type: Disease specific,Hospital | data categories: Medical records,Physiological/Biochemical measurements | materials: Plasma,Serum | omics: Not available | imaging: N | sex: Female,Male
Investigation whether low-level, aiming for serum concentrations 0.5-0.9ng/mL, digoxin on top of standard treatment (guideline-recommended therapy), is beneficial in HF patients with reduced or mid-range ejection fractions (LVEF ≤50%); in a double-blind placebo controlled clinical trial.
Digoxin Evaluation in Chronic heart failure: Investigational Study In Outpatients in the Netherlands
DECISION
collection type: Cohort,Disease specific,Hospital,Longitudinal | disease: Ischaemic heart diseases | data categories: Medical records,Physiological/Biochemical measurements,Survey data | materials: Not available | omics: Not available | imaging: N | sex: Female,Male
BENEFIT is an ecosystem for healthy living and an integrated loyalty program that rewards patients for the time and energy spent on healthy lifestyle activities. By rewarding everyday lifestyle and adherence behaviors, the program integrates care and non-care settings and facilitates embedding the new lifestyle in everyday life.
BENEFIT for all: The Ecosystem for Healthy Living
BENEFIT
Longitudinal
collection type: Case-Control,Hospital,Image collection,Population-based | disease: Angina pectoris,Acute myocardial infarction,Subsequent myocardial infarction,Certain current complications following acute myocardial infarction,Other acute ischaemic heart diseases,Chronic ischaemic heart disease | data categories: Biological samples,Imaging data,National registries | materials: Plasma,Whole Blood | omics: Not available | imaging: Y | sex: Female,Male
Population-based study investigating the diagnostic yield of stress perfusion MRI for early detection of coronary heart disease in asymptomatic individuals with increased calcium scores. In addition, cost-effectiveness of a diagnostic screening algorithm for cardiovacular disease will be studied.
Early detection of 'silent' myocardial ischemia and cardiac dysfunction in asymptomatic individuals with increased coronary artery calcium scores
Acute myocardial infarction
Angina pectoris
Certain current complications following acute myocardial infarction
Chronic ischaemic heart disease
Early-Synergy
Other acute ischaemic heart diseases
Subsequent myocardial infarction
Whole Blood
Patiënten (kinderen en volwassenen) die een congenitale cardiochirurgische ingreep hebben ondergaan.
De congenitale cardiothoracale chirurgie registratie omvat alle uitgevoerde congenitale cardiochirurgie ingrepen bij kinderen en volwassenen.
Congenitale cardiothoracale chirurgie
CCTC
congenital cardiac surgery
congenital heart disease CHD
open-heart surgery
collection type: Cohort,Hospital,Population-based | disease: Heart disease, unspecified | data categories: Medical records,Physiological/Biochemical measurements | materials: Not available | omics: Not available | imaging: N | sex: Female,Male
The aim of CAPACITY is to collect data regarding the cardiovascular history, diagnostic information and occurrence of cardiovascular complications in COVID-19 patients. By collecting this information in a standardized manner, CAPACITY can aid in providing more insight in (1) the incidence of cardiovascular complications in patients with COVID-19, and (2) the vulnerability and clinical course of COVID-19 in patients with an underlying cardiovascular disease.
Cardiac complications in Patients with SARS Corona virus 2 registry
CAPACITY-COVID Registry
Heart disease
unspecified
collection type: Cohort,Longitudinal,Rare disease collection,Sample collection | disease: pulmonary arterial hypertension | data categories: Biological samples,Imaging data,Medical records,Survey data | materials: Peripheral blood cells,Plasma,Serum,Urine,Whole Blood | omics: Not available | imaging: Y | sex: Female,Male
longitudinal follow-up program for early detection of PAH in unaffected carriers. these carriers are compared with Idiopathic PAH patients, heritable PAH patients and healthy controls.
Detection Of Latent Pulmonary Hypertension In Genetically Susceptible Individuals
DOLPHIN-GENESIS
Peripheral blood cells
Rare disease collection
Urine
pulmonary arterial hypertension
collection type: Cross-sectional,Disease specific,Image collection | disease: Cardiomyopathy | data categories: Biological samples,Imaging data,Medical records,Physiological/Biochemical measurements,Survey data | materials: Serum,Whole Blood | omics: Not available | imaging: Y | sex: Female,Male,Undifferentiated
We collected cardiac data (history, phusica; examination, Echo, ECG, Blood) from 1550 chidlhood cancer survivors and 250 sibling.
Early detection of cardiac dysfunction in childhood cancer survivors; a LATER study
Cardiomyopathy
LATER CARD
collection type: Other | disease: Type 2 diabetes mellitus,Cardiovascular disease, unspecified | data categories: Physiological/Biochemical measurements,Survey data,Other | materials: Not available | omics: Not available | imaging: N | sex: Female,Male
Een gezonde leefstijl - een gezond voedingspatroon en voldoende bewegen - draagt in belangrijke mate bij aan de preventie van chronische ziekten. Mensen met lage sociaal-economische status (SES) hebben vaak een ongezondere leefstijl dan mensen met een hogere SES. Echter, interventies gericht op het stimuleren van een gezonde leefstijl bereiken juist deze lage SES doelgroep slecht en kunnen sociale ongelijkheid vergroten. Een mogelijke verklaring hiervoor is dat interventies zich traditioneel veelal richten op individuele determinanten van gedrag zoals kennis, attitudes en intenties. Bovendien zijn deze interventies veelal niet effectief, mede doordat er geen rekening gehouden wordt met de - sociale, fysieke en politieke - context waarin leefstijlkeuzes gemaakt worden: ongezond gedrag kan worden gezien als een automatische reactie op de 'obesogene' omgeving. Veranderingen in en van de omgeving waarin mensen leven kunnen in belangrijke mate helpen om een gezonde leefstijl te bevorderen en alle doelgroepen te bereiken. Door veranderingen in de omgeving moet gezorgd worden dat de gezonde keuze de makkelijke keuze, de voor de hand liggende keuze of zelfs de enige keuze wordt, juist ook voor de moeilijke bereikbare en veranderbare doelgroepen zoals mensen met een lagere opleiding. Echter, of omgevingsinterventies ook op langere termijn effectief zijn voor het verbeteren van risicofactoren voor hart- en vaatziekten is niet bekend en moet onderzocht worden. In SUPREME NUDGE wordt een geïntegreerde interventie in supermarkten ontwikkeld en onderzocht, waarin de 'supermarktomgeving' zo wordt ingericht dat de gezonde voedselkeuze makkelijker en vanzelfsprekender wordt. De supermarkt is een belangrijke omgeving waarin (leefstijl)keuzes worden gemaakt, en waar het verleiden tot gezondere voedingskeuzes via productplaatsing, prijsverandering en berichten directe en langdurende effecten kan hebben. Dit wordt gecombineerd met een m-health promotion interventie waarmee mensen direct en op maat feedback en adviezen krijgen over hoeveel ze waar en wanneer bewegen, en hoe ze meer kunnen gaan bewegen. De effecten op risicofactoren voor hart- en vaatzieken worden onderzocht. Deze interventie bouwt voort op eerdere effectieve interventies om gezonde voeding en voldoende beweging te bevorderen, maar combineert twee innovatieve benaderingen: 'nudging' en prijsverandering, met 'real-time' feedback waarbij gebruik wordt gemaakt van kunstmatige intelligentie en context-specifieke informatie en adviezen over leefstijlgedrag.
SUstainable PREvention of cardioMEtabolic risk through NUDGing hEalth behaviors
Cardiovascular disease
SUPREME NUDGE
Type 2 diabetes mellitus
collection type: Rare disease collection | disease: Dilated cardiomyopathy | data categories: Biological samples,Imaging data,Medical records,National registries,Physiological/Biochemical measurements | materials: DNA,Plasma,Serum,Whole Blood | omics: Genomics | imaging: Y | sex: Female,Male
A campaign to inform the general public and online tools to evaluate indications for cardiogenetic referral will be launched. The yield of novel methods to reach out to family members will be investigated and if successful, implemented into routine cascade testing. Advanced non-invasive imaging and non-invasive electrophysiological measurements will be performed in mutation carriers and asymptomatic family members to detect early signs of cardiac disease, with special attention to sex differences. As exemplar for all inherited cardiomyopathies, early detection at individual and cellular level will focus on patients and their family members with PLN or PKP2 gene founder mutations. Early detection facilitates risk stratification and timely therapeutic interventions, thereby reducing mortality and morbidity. A national infrastructure will be developed to facilitate biomarker discovery and follow-up research. Extensive genetic and phenotypic (including imaging) data will be stored and integrated into a central data warehouse to facilitate data sharing and guarantee long-term sustainability of the registries. As such, e-DETECT will help in the prevention of cardiac dysfunction and SCD among young, apparently healthy individuals. By 2030, the consortium aims to increase the uptake of cascade testing in family members by 50% and thereby detect up to 25% more patients at true risk. This increased uptake will enable regular follow up and timely treatment, thereby reducing morbidity and mortality.
Early detection of disease in cardiomyopathy mutation carriers
Dilated cardiomyopathy
eDETECT
collection type: Cohort,Disease specific,Image collection | data categories: Imaging data,Medical records | materials: Not available | omics: Not available | imaging: Y | sex: Female,Male,Undifferentiated
The CAS study is a clinical observational study investigating the effects of ConAoS on the left ventricular function and the prevalence, pattern and expanse of LVH, myocardial stiffness and myocardial fibrosis. Moreover, we will assess the prognostic capacity of the presence of these pathological processes, correlating our findings at baseline to clinical outcome by assessing the occurrence of cardiovascular events and all-cause mortality during 3-year clinical follow-up. We will unravel biomarker and imaging predictors for myocardial dysfunction (systolic and diastolic) with specific attention for male-female differences
OUTREACH
Volwassenen van 18 jaar of ouder die een eerste hartfalen diagnose hebben gekregen.
De Hartfalen registratie omvat patiënten met hartfalen die voldoen aan de richtlijnen en definitie ESC 2021 en 2023 focused update. De inclusie betreft in ieder geval de Novo HF patiënten met HFrEF, die primair voor hun hartfalen op de poli komen (+/- klinische opname vooraf) voor instellen van hun diagnose en behandeling van hartfalen. Voor de Hartfalen-registratie worden de patiënten tot 1 jaar na hun diagnose opgevolgd tenzij de patiënt eerder teruggaat naar de eerstelijn, overlijdt of wordt doorverwezen.
Hartfalen registratie
CHF
HFmrEF
HFpEF
HFrEF
left ventricular dysfunction
collection type: Other | disease: Other specified degenerative diseases of nervous system | data categories: Imaging data | materials: Not available | omics: Not available | imaging: Y | sex: Female,Male
To optimally use brain imaging data in vascular cognitive impairment (VCI), the ImProVas project (i) develops and validates methods for automatic quantification of microbleeds and lacunar infarcts and (ii) develops and validates prediction methods utilizing these biomarkers. The project extends existing cohorts with novel image-derived biomarkers (HBC: https://www.ncbi.nlm.nih.gov/pubmed/29017156; TRACE-VCI: https://www.ncbi.nlm.nih.gov/pubmed/28428166).
Improved Prognosis of Vascular cognitive impairment using automatic quantitative imaging biomarker extraction and disease modeling
ImProVas
Other specified degenerative diseases of nervous system
collection type: Cohort,Disease specific,Image collection | disease: Other cerebrovascular diseases - Cerebral aneurysm, nonruptured | data categories: Imaging data | materials: Not available | omics: Other | imaging: Y | sex: Female,Male
We aim to improve rupture risk prediction by technical innovations 1) enabling automatic assessment of the UIA shape (including size), 2) determining the effect of the bloodflow on the UIA, and 3) by using machine learning methods (feature learning) to make predictions for rupture based on automatically learned aneurysm characteristics.
ANEURYSM@RISK: automatic intracranial aneurysm quantification, 4D flow MRI and feature learning modelling to optimize intracranial aneurysm rupture prediction.
Aneurysm risk
collection type: Hospital,Longitudinal,Population-based,Rare disease collection | data categories: Medical records,Physiological/Biochemical measurements | materials: Not available | omics: Genomics | imaging: Y | sex: Female,Male
Development of deep neural networks for automated analysis of electrocardiograms (ECGs) and of a medical device to obtain a multi-lead device at home. Both innovations will be integrated in this project to improve the value of the ECG both at home and in the hospital.
Deep neural networks for ECG interpretation and home cardiac monitoring
ECGnet
collection type: Cohort,Sample collection | disease: Mitral valve disease, unspecified | data categories: Biological samples,Imaging data,Physiological/Biochemical measurements | materials: DNA,Peripheral blood cells,Plasma,Serum,Whole Blood | omics: Not available | imaging: Y | sex: Female,Male
CCTA and adenosine CMR imaging of women and men with chest pain symptoms
CVON ARGUS
ARGUS
Mitral valve disease
collection type: Cohort | data categories: Physiological/Biochemical measurements | materials: Not available | omics: Not available | imaging: N | sex: Female,Male
In the TRANS study, the effect of hormone use on platelets and inflammation markers is being investigated.
The effect of testosterone on platelet activation and inflammation intransgender men
TRANS
Patiënten (kinderen en volwassenen) die een transcatheter hartklepinterventie hebben ondergaan.
De Transcatheter Hartklepinterventie (THI) registratie omvat de volgende interventies: • transcatheter aortaklepimplantaties (TAVI) • transcatheter-mitralisklepingrepen • transcatheter-tricuspidalisklepingrepen • plaatsing van plugs ten behoeve van paravalvulaire lekkage (PVL)-sluiting • uitvoeren Percutaneous Aortic Balloon Valvuloplasty (PABV) dilatatie Hier geldt dat elke poging tot een ingreep wordt geïncludeerd vanaf het moment dat de patiënt is aangeprikt en/of een huidincisie heeft plaatsgevonden.
THI registratie
Percutaneous valve replacement
TAVI
TMVR
collection type: Other | disease: Cerebral infarction, unspecified | data categories: Imaging data | materials: Not available | omics: Not available | imaging: Y | sex: Not available
Proper treatment selection in the acute phase of ischemic stroke can considerably improve patient outcome, as shown by recent studies. In the setting of acute stroke, treatment selection can be optimized using important information based on CTA imaging data. Currently this data is only assessed qualitatively, hence large opportunity for improving the use of CTA imaging data exists. Advanced decision support models that include accurate and objective quantification of CTA imaging biomarkers have the potential to greatly improve on current clinical practice. The ACCURATE project aims to develop and validate methods for the automated analysis of CTA data acquired in acute stroke phase. Additionally, the added value of such analyses for treatment selection support in the acute stroke stage will be determined within the scope of this project.
Automatic CTA Image Analysis to Support Treatment Selection in Acute Stroke
Accurate
Cerebral infarction
collection type: Cohort,Disease specific,Image collection,Longitudinal,Sample collection | disease: Cardiomyopathy - Other cardiomyopathies | data categories: Biological samples,Imaging data,Medical records,Physiological/Biochemical measurements,Survey data | materials: cDNA / mRNA,DNA,Plasma,RNA,Serum,Tissue, cryo preserved,Tissue, paraffin preserved,Whole Blood | omics: Genomics,Metabolomics,Proteomics,Transcriptomics | imaging: Y | sex: Female,Male
Inherited cardiomyopathies (CM) are clinically heterogeneous: age of onset and disease-severity differ greatly between patients with the exact same gene mutation. The mechanisms that underlie the variation in disease susceptibility are unknown. Pilot data of DOSIS suggest an important role for secondary disease-modifiers such as additional (epi)genetic variations, environmental disease triggers, and an age-related decline in protein quality control (PQC). The PQC system prevents onset of CM by suppressing the accumulation of toxic proteins in cardiomyocytes. Moreover, CM severity is attenuated by the stimulation of protein degradation pathways. Thus, a healthy PQC system keeps mutant expression below the toxic dose. In addition, mutation location in a gene may determine disease susceptibility due to specific mutation-induced changes in protein structure, which alter PQC recognition, and affect incorporation into the sarcomere. Hypothesis: the clinical variability in CM is determined by (1) interplay between (epi)genetic and ageing-induced environmental factors (burden); (2) status of the PQC system (coping mechanisms); (3) mutation location. Aims: 1. Identify (epi)genetic modifiers influencing the CM phenotype in individuals carrying a sarcomeric mutation. 2. Elucidate derailment of the PQC system as determinant of cellular toxicity in CM. 3. Establish the toxic effect of mutants with respect to protein dose and mutation location. 4. Obtain proof of concept for age-dependent secondary disease-modifiers as key players in protein toxicity of CM mutations and test novel pharmacological interventions. DOSIS is directed at understanding the path a mutation needs to travel to become toxic, and at testing novel therapies in experimental model systems.
DETERMINANTS OF SUSCEPTIBILITY IN INHERITED CARDIOMYOPATHY: TOWARDS NOVEL THERAPEUTIC APPROACHES
Cardiomyopathy - Other cardiomyopathies
DOSIS
Metabolomics
RNA
Transcriptomics
paraffin preserved
Volwassenen van 18 jaar of ouder die een endocarditis diagnose hebben gekregen.
De Endocarditis registratie omvat elke patiënt die binnen het endocarditis team wordt besproken, waarbij de diagnose ‘possible’ of ‘definite’ infectieuze endocarditis (IE) wordt gesteld. Hierbij geldt dat elke nieuwe ziekte-episode van een patiënt wordt aangeleverd. Onder IE wordt verstaan: een microbiële ontsteking van het intracardiale endotheel en/of lichaamsvreemd implantaat (zoals een pacemaker of kunstklep) waarbij voor diagnose de modified Duke criteria en/of European Society of Cardiology (ESC) endocarditis criteria worden gebruikt.
Endocarditis registratie
Prosthetic valve endocarditis
antibiotic therapy
bacterial endocarditis
endocarditis
native valve endocarditis
collection type: Other | disease: Chronic ischaemic heart disease | data categories: Biological samples,Imaging data | materials: Peripheral blood cells,Plasma | omics: Proteomics | imaging: Y | sex: Not available
see below
Low Dose Colchicine for Secondary Prevention of CV disease
collection type: Disease specific,Image collection | disease: Cardiomyopathy - Endocardial fibroelastosis | data categories: Genealogical records,Imaging data,Other | materials: Not available | omics: Not available | imaging: Y | sex: Female,Male
Electrocardiographic imaging in patients to identify early signs of disease in arrhytmogenic cardiomyopathy. Therefore, clinical MRI/CT, body surface mapping (64-electrode ECG) and 3D imaging of the electrode positions is carried out.
QRS vectors in Solving the Inverse Problem of Electrocardiography
Cardiomyopathy - Endocardial fibroelastosis
Genealogical records
QRS-Vision
collection type: Hospital,Non-Human | disease: Atherosclerosis | data categories: Biological samples,Imaging data | materials: cDNA / mRNA,Peripheral blood cells,Plasma,RNA,Serum | omics: Genomics,Transcriptomics | imaging: N | sex: Female,Male
We have from the atheroexpress biobank (UMCU) cell isolates from atherectomy samples and blood cells
GENIUS II
Atherosclerosis
collection type: Hospital,Longitudinal,Sample collection,Other | disease: Pneumonia due to staphylococcus aureus | data categories: Physiological/Biochemical measurements | materials: Not available | omics: Not available | imaging: N | sex: Female,Male
We investigated whether hyperaggregation occurs during infection, and whether aspirin inhibits this. Patients hospitalised due to acute infection were randomised to receive 10 days of aspirin treatment or no intervention. Our outcome measures were PFA-Closure Time, serum thromboxane and plasma thromboxane.
The efficacy of aspirin to inhibit platelet aggregation in patients hospitalised with a severe infection: a multicentre, open‑label, randomised controlled trial
ASPIRIN
Pneumonia due to staphylococcus aureus
collection type: Case-Control,Disease specific,Longitudinal,Population-based | data categories: Imaging data,Medical records,Physiological/Biochemical measurements,Survey data | materials: Serum | omics: Not available | imaging: Y | sex: Female,Male
Rationale: Tetralogy of Fallot is the most common type of cyanotic congenital heart disease. The main problems of this patient population are heart failure related to chronic pulmonary regurgitation, arrhythmias and sudden cardiac death. A major gap in our knowledge is how coupling between the RV and pulmonary artery affects outcomes. It has been shown that aortic pulse wave velocity can be improved by exercise training in Tetralogy of Fallot. Objective: Primary Objective: To examine the effect of an online based exercise training protocol on ventriculo-arterial coupling , as assessed by pulse wave velocity in the aorta and pulmonary artery in patients operated for Tetralogy of Fallot. Study design: cross-over interventional study. All children and young adults will be randomized in 2 groups. One group will start with care/exercise as usual, the other group will start with an online exercise training. After 12 weeks the groups will change from protocol. Before start of measurements, after 12 weeks and group 2 after 24 weeks, all participants will undergo a number of tests, including echocardiogram, cardiopulmonary exercise test, and cardiac magnetic resonance imaging. Study population: 12-30 years of age, after surgical repair of tetralogy of Fallot (TOF), being followed at one of the 2 locations of the Academic Center for Congenital Heart disease (ACAHA). Intervention: 12 weeks of online based interval training 3 times a week. Main study parameters/endpoints: Decrease in pulse wave velocity in the aorta and pulmonary artery measured by MRI.
Outflow tract related aging with congenital heart disease. Workpackage Tetraogy of fallot High Intensity Interval Training
OUTREACH ToFHIIT study
collection type: Cohort,Disease specific,Hospital | data categories: Imaging data,Medical records,Physiological/Biochemical measurements,Survey data | materials: Not available | omics: Not available | imaging: Y | sex: Female,Male
With our project we strive to maximally utilize existing data and registries. However, new data needs to be collected, primarily due to three reasons: (1) routine clinical care so far has lacked standardized diagnostic tests for the detection of myocardial damageafter COVID-19; (2) the established cohorts have no funding for repeated measurements/follow-up to assess the (ir)reversibility of myocardial damage and (3) no patient reported outcome data are available that could function as a potential alert of ongoing myocardial problems following COVID-19.
DEFENCE: Determination and Evaluation of the Frequency and Effects of myocardial damage iNpatients with a SARS-CoV-2 infEction
DEFENCE
collection type: Cross-sectional,Disease specific,Longitudinal | data categories: Survey data,Other | materials: Not available | omics: Not available | imaging: N | sex: Female,Male
The multidisciplinary ArmCoach4Stroke project aims to develop and evaluate a new and interactive therapy aid based on movement sensors to stimulate and optimize the daily use and exercise of the affected arm in the home environment by objective, personalized feedback to the patient and his/her therapist.The ArmCoach4Stroke will be developed in co-creation with patients and therapists and other (end)users, with focus on optimal implementation in health care.
ArmCoach4Stroke
collection type: Other | disease: Atherosclerosis | data categories: Biological samples | materials: cDNA / mRNA,Cell lines,DNA,RNA,Tissue, cryo preserved,Other | omics: Not available | imaging: N | sex: Not available
High total cholesterol levels are a major cause of disease burden in both the developed and developing world as a risk factor for ischemic heart disease and stroke. Lowering cholesterol has been one of the most effective strategy to prevent major cardiovascular event. In this study, we will try to develop a new treatment for hypercholesterolemia by permanently removing PCSK9 from hepatocytes by using cell-derived vesicles.
Technology Of Protein delivery through Extracellular Vesicles to target PCSK9
TOP-EVs
collection type: Hospital | disease: hartfalen | data categories: Biological samples,Imaging data,Medical records,Physiological/Biochemical measurements,Survey data,Other | materials: Feaces,Other | imaging: Y | sex: Undifferentiated
We investigate diagnostic technologies to reduce cardiovascular disease. We use questionnaires, serious gaming, electrocardiography, digital stethoscopes and other eHealth techniques. Big data analytics are used to study patterns.
Self TRAcking for Prevention and diagnosis of heart disease
Feaces
STRAP
hartfalen
collection type: Cohort,Hospital,Longitudinal,Sample collection | disease: Primary pulmonary hypertension | data categories: Biological samples,Imaging data,Medical records,Survey data | materials: Peripheral blood cells,Plasma,Serum,Urine,Whole Blood | omics: Metabolomics | imaging: Y | sex: Female,Male
longitudinal follow-up program for unaffected mutation carriers at risk for developing pulmonary arterial hypertension
Primary pulmonary hypertension
collection type: Case-Control,Disease specific,Population-based | disease: Cardiac arrest,Type 2 diabetes mellitus | data categories: Medical records,Physiological/Biochemical measurements | materials: DNA,Plasma | omics: Genomics,Metabolomics | imaging: N | sex: Female,Male
The RESCUED study investigates the risk of a sudden cardiac arrest in diabetes patients. The aim is to improve recognition of individuals at high risk of sudden cardiac arrest focussed on the General Practitioner and molecular markers.
Recognizing sudden cardiac arrest vulnerability in diabetes
Cardiac arrest
RESCUED
collection type: Birth cohort,Cohort,Disease specific,Non-Human,Population-based | disease: Atherosclerosis,Obesity | data categories: Biological samples,Imaging data,Physiological/Biochemical measurements | materials: cDNA / mRNA,DNA,Feaces,Peripheral blood cells,Plasma,RNA,Serum,Tissue, cryo preserved,Tissue, paraffin preserved | omics: Genomics,Metabolomics,Proteomics,Transcriptomics | imaging: Y | sex: Female,Male
IN-CONTROL II will seek to i. unravel the mechanisms driving 'trained immunity" in patients, taking into account the impact of senescence, age, gender and obesity, ii. elucidate the interactions between microbiome-derived signals and (immune) senescence in the etiology of obesity-related cardio-metabolic diseases, and iii. to pursue and to identify new therapeutic targets and to design novel pharmacological and microbiome-based therapies to counteract inappropriate induction of trained immunity and inflammatory processes in cardiovascular disease.
Inflammatory Reprogramming by Ageing and Microbiome - Targets for Treatment of Cardiovascular Disease
Birth cohort
IN-CONTROL II
Obesity
collection type: Cohort,Longitudinal | disease: Atherosclerotic heart disease,Heart failure,Atrial fibrillation and flutter | data categories: Biological samples,Physiological/Biochemical measurements,Survey data | materials: Serum | omics: Not available | imaging: N | sex: Female,Male
A diagnostic cluster randomized trial in patients participating in primary care disease management programs for COPD or type 2 diabetes. An early diagnosis strategy will be compared with usual care (650 vs. 650 participants). primary end point: difference in number of newly diagnosed cases of heart failure, atrial fibrillation or coronary artery disease between the two arms.
REVIVING EARLY DIAGNOSIS OF CARDIOVASCULAR DISEASE
Heart failure
RED-CVD
Volwassenen van 18 jaar of ouder die een cardiochirurgische ingreep hebben ondergaan.
De Cardiochirurgie registratie omvat uitgevoerde cardiochirurgische ingrepen aan het hart en/of de grote intrathoracale vaten, al dan niet in combinatie met een niet-cardiale ingreep. Een sessie beslaat de periode vanaf het moment van huidincisie of -punctie tot en met het verlaten van de operatiekamer of de ruimte waar de interventie heeft plaatsgevonden. Ook afgebroken interventies nadat er al een huidincisie of -punctie heeft plaatsgevonden vallen binnen een sessie zijn geïncludeerd.
Cardiochirurgie registratie
ATAD
AVR
CABG
CTC
MVP
MVR
aortic surgery
heart valve surgery
collection type: Disease specific,Image collection,Non-Human,Rare disease collection | disease: Primary pulmonary hypertension | data categories: Biological samples,Imaging data,Physiological/Biochemical measurements | materials: cDNA / mRNA,Cell lines,Peripheral blood cells,Plasma,RNA,Serum,Tissue, cryo preserved,Tissue, paraffin preserved,Whole Blood | omics: Transcriptomics | imaging: Y | sex: Female,Male
PAH is a deadly disease characterized by abnormal remodelling of pulmonary vessels, leading to a progressive increase in pulmonary artery pressure and right heart failure. PHAEDRA-IMPACT aims to prevent disease development by early identification of the patient at risk, and identification and treatment of treatable traits in different forms and stages of the disease.
Pulmonary Hypertension and AssociatED Right heart fAilure: IMproved outcomes through Precision medicine, Advanced modelling and early deteCTion
PHAEDRA-IMPACT
collection type: Other | disease: Atherosclerotic heart disease | data categories: Imaging data,Medical records | materials: Not available | omics: Not available | imaging: Y | sex: Female,Male
CONCRETE aims to evaluate whether GP access to CT calcium scoring leads to earlier CAD diagnosis and treatment. The design is a pragmatic cluster randomized trial in which direct access to CT calcium scoring is compared to routine clinical care in patients with chest discomfort. Randomization will take place at GP level. Patients in both clusters will be asked for consent to fill in questionnaires and for the researchers to gather data on work-up and follow-up.
COroNary Calcium scoring as fiRst-linE Test to dEtect and exclude coronary artery disease in GP patients with stable chest pain
CONCRETE
collection type: Cohort,Disease specific,Hospital,Longitudinal | data categories: Imaging data,Medical records,Physiological/Biochemical measurements,Survey data | materials: Not available | omics: Not available | imaging: Y | sex: Female,Male
For this reason, there is an urgent need for large prospective cohort studies in which patients with laboratory confirmed COVID-19 unselectively undergo standardized and long-term follow-up to assess the occurrence and natural history of cardiac abnormalities. In the current study, we aim to determine if and how often (residual) cardiac damage can be detected in patients who have recovered from COVID-19. Furthermore, we strive to gain additional insight into the etiology in patients that develop (residual) damage of the heart.
CAPACITY 2: A prospective cohort study evaluating the occurrence of short and long-term cardiac and cerebrovascular complications in patients hospitalized for COVID-19
CAPACITY2
collection type: Cohort,Disease specific,Hospital,Sample collection | data categories: Biological samples,Medical records | materials: cDNA / mRNA,Peripheral blood cells,Plasma,RNA,Whole Blood | omics: Not available | imaging: N | sex: Female
This project aims at investigating if the mechanism of trained immunity plays a role in the development of atherosclerosis in women with former preeclampsia.
IMPRESS
collection type: Disease specific,Hospital,Image collection,Longitudinal,Non-Human,Rare disease collection | disease: Congenital insufficiency of aortic valve | data categories: Biological samples,Imaging data,Medical records | materials: DNA,Plasma,Serum | omics: Genomics | imaging: Y | sex: Female,Male
The bicuspid aortic valve is generally considered to be a result of a congenital fusion of two out of three leaflets. We found that the non-coronary leaflet develops from the same embryonic structure that also gives rise to the right coronary leaflet. A BAV type 2 can be considered as the result of an improper separation rather than an abnormal fusion of two separately developed leaflets, which is an essential different starting point for our research to explore the genetic and signalling pathways of BAV genesis. We also have found in a bicuspid aortic model (NOS3 knock out) that 2 out 3 contributing extracardiac cell populations (neural crest and second heart field) are disturbed in their contribution to both the aortic valvular leaflets and the aorta wall. This results in BAV and abnormal elastin production in the ascending aortic wall from its initial formation in the embryo onwards. Hemodynamics seems to play a more modest role in the formation of the aorta aneurysm than one has generally considered up till now. To study the role of haemodynamics in EMT during valve formation and calcification we made use of the ex vivo miniature tissue culture system. In cultured mouse adult hearts, we found that by changing flow, the response of valve endothelial cells is altered. By culturing valves of mice with a genetic endothelial lineage trace, we could show that when exposed to high physiological flow, the endothelial cell phenotype and lining is maintained. Interestingly, by adding calcification inducing factors such as B-glycerolphosphate, dexamethasone or Bone Morphogenetic Proteins, we were able to induce valvular calcification in the cultured adult mouse hearts. We further studied the role of haemodynamics in the pathology of BAV by immunoshistochemical analysis of aortic material. We observed that at the non-jet side of the aorta the endothelial cells showed a significantly increased inflammation (P50+), endothelial-to-mesenchymal-transition (SNAI1+) and trend towards increased proliferation in BAV patients. Our results show an increased endothelial activity at the inner curvature of the ascending aorta/aortic arch with oscillatory flow in BAV patients. In human aortic samples from BAV patients, we have identified that the protein FHL2 is increased in the dilated aorta compared with the non-dilated aorta. FHL2 is an interesting biomarker as it has been described to reduce smooth muscle cell contractility. Our observed increase in FHL2 expression in the dilated aorta could therefore be related to an increase in synthetic SMCs, causing the breakdown of the elastic lamellae and destabilization of the aorta. We investigated women with Turner syndrome using advanced imaging technology to study structural abnormalities. We focused on partial abnormal pulmonary venous return and found that 25% of the women indeed had this abnormality, a much higher prevalence than expected. In addition, we discovered structural abnormalities in the aortic arch, large arteries and coronary arteries. This last finding is completely new. We also investigated the aorta flow with 4D MRI in patients with BAV and demonstrated the feasibility of this technique to estimate regurgitation and showed good correlation with echocardiography. Of patients with coarctation, approximately 50% to 75% have a bicuspid aortic valve. We found that coarctation stent treatment in Turner patients is associated with a higher risk than normal. Finally, we investigated the risk of dissection and found a lower risk than expected. Aortic stenosis is the most frequent complication of bicuspid aortic valve and the main reason for valve surgery during lifetime. Different options for valve replacement are available and we investigated the outcomes for the different options in children and adults. Then an information portal was developed according to the systematic International Patient Decision Aid Standards (IPDAS) development process. First, we conducted comprehensive surveys and interviews among patients (N=63), caregivers of pediatric patients (N=10) and physicians (N=32) to assess the current state of patient information and explore their preferences and needs, to determine the focus for the development of the information portal. We found that patient knowledge and numeracy is limited, reliable information is scarce, physicians inform patients selectively and patient involvement is suboptimal. Then we tested the impact of the information portal on the subjective quality of life. We found no effect, however, when studying the results in more detail we found that 50% of the patients never visited the website and that in the patients who did visit the website there was a clear positive effect on the quality of life. We discovered a new gene mutation on SMAD6 in patients with a bicuspid aortic valve that is associated with aortic aneurysm. Also we discovered TBX20 as a contributing gene. Finally, loss-of-function mutations in the X-linked biglycan gene were found to cause a severe syndromic form of thoracic aortic aneurysms and dissections.
UNRAVELLING AETIOLOGY AND RISK FACTORS IN PATIENTS WITH A BICUSPID AORTIC VALVES
BAV
Congenital insufficiency of aortic valve
collection type: Other | disease: Obesity | data categories: Medical records,Survey data | materials: Not available | omics: Not available | imaging: N | sex: Female,Male
In the five year LIKE programme (2017-2022), we develop, implement and evaluate an integrated action programme at the level of family, school, neighbourhood, health care and city, based upon a detailed insight into the characteristics of the population at stake. The aim is to tackle the wicked problem of childhood overweight and obesity in 10-14 year old adolescents in Amsterdam, using a systems dynamics and participatory approach. Following the principles of Participatory Action Research (PAR), we work with our population (adolescents and their families) and societal stakeholders as co-creators and co-investigators.
Lifestyle Innovations Based on youth's Knowledge and Experience
LIKE
collection type: Disease specific,Hospital,Longitudinal | disease: I48.0 Atriumfibrilleren | data categories: Biological samples,Medical records | materials: Plasma,Whole Blood | omics: Not available | imaging: N | sex: Female,Male
multicenter, prospective randomised controlled trial to evaluate the efficacy of a watchful waiting strategy (rate control for symptom relief) compared to routine care (cardioversion) for patients with recent-onset symptomatic paroxysmal atrial fibrillation presenting to the emergency department.
Device-based rate versus rhythm control treatment in patients with symptomatic recent-onset atrial fibrillation in the emergency department (RACE 9)
I48.0 Atriumfibrilleren
RACE 9 Observe-AF
Volwassenen van 18 jaar of ouder die een PCI hebben ondergaan.
De Percutane Coronaire Interventie (PCI) registratie omvat elke interventie waarbij een instrument (guide wire, ballon, trombosuctie katheter, rotablator, etc.) in één van de coronairen of in de coronaire arteriële bypass graft ingebracht wordt met de intentie om het desbetreffende bloedvat te behandelen. De geïsoleerde diagnostische metingen zijn niet geïncludeerd.
PCI registratie
CAD
Coronary artery disease
Interventional cardiology
NSTEMI
PCI
Percutaneous coronary intervention
STEMI
stent
collection type: Other | disease: Heart failure | data categories: Other | materials: Not available | omics: Not available | imaging: N | sex: Female,Male
large small molecule screen to identify compounds that enhance 5-oxoprolinase activity.
ESCAPE-HF
collection type: Cohort,Cross-sectional,Hospital,Longitudinal,Population-based | disease: Diseases of the circulatory system | data categories: Imaging data,Medical records,National registries,Survey data | materials: Not available | omics: Not available | imaging: Y | sex: Female,Male
Within DEFENCE, all large national COVID-19 studies aimed at unravelling the relationship between cardiovascular disease and COVID-19 are brought together. The main aim of DEFENCE is to unravel the prevalence and consequences of myocardial damage of COVID-19.
Determination and Evaluation of the Frequency and Effects of myocardial damage iN patients with aSARS-CoV-2 infEction
Diseases of the circulatory system
collection type: Cohort,Cross-sectional,Disease specific,Hospital,Image collection,Longitudinal,Population-based | disease: Atrial fibrillation and flutter,Occlusion and stenosis of carotid artery,Heart failure,Other and unspecified symptoms and signs involving cognitive functions and awareness | data categories: Biological samples,Imaging data,Physiological/Biochemical measurements,Survey data,Other | materials: Liquor,Plasma,Serum | omics: Not available | imaging: Y | sex: Female,Male
Cognitive impairment is common among people with cardiovascular or cerebrovascular disease. HBC1 explored the etiological role of hemodynamic factors in cognitive impairment, particularly addressing flow. HBCx builds on the same hypothesis, now taking a multidimensional approach, also addressing flow regulation and variability and factors that modulate the impact of hemodynamic disturbances.
Heart-Brain Connection & Heart-Brain Connection - crossroads
HBC HBCx
Liquor
Occlusion and stenosis of carotid artery
Other and unspecified symptoms and signs involving cognitive functions and awareness
collection type: Cohort,Disease specific,Rare disease collection,Sample collection | disease: Dilated cardiomyopathy | data categories: Biological samples,Imaging data,Medical records,National registries,Physiological/Biochemical measurements | materials: DNA,Plasma,Serum | omics: Genomics | imaging: Y | sex: Female,Male
Dilated cardiomyopathy is a major cause of heart failure and is the main indication of cardiac transplantation. About 30-50% of the cases can be explained by genetic predisposition. However, the precise mechanisms that lead to variations in disease susceptibility and phenotype presentation including risk for heart failure or sudden cardiac death are thus far unknown. The DETECTIN-HF project will work with selected clinical and molecular markers in a multi-center, multi-national cohort. The facility which arises by creating this single, harmonized portal is unique in setup and scale and is invaluable for research and improved clinical practice.
DETECTIN-HF
collection type: Hospital | data categories: Imaging data,Medical records,National registries,Physiological/Biochemical measurements,Survey data,Other | imaging: Y | sex: Undifferentiated
The MyDigiTwin consortium will build the MyDigiTwin platform on top of the Personal health record depositories (Dutch: Persoonlijke Gezondheidsomgeving; PGO), enabling users to build "digital twins" of themselves with their personal health data in order to gain a better understanding of their (heart) health, but also the effect of possible lifestyle changes. Through MyDigiTwin, users can perform analyses with their own data, take control of their own health monitoring, detect possible risks of heart disease at an early stage and go to a doctor in time.
MyDigiTwin: Using Big-Data to put a cardiovascular digital twin into the hands of people.
MyDigiTwin
collection type: Case-Control,Cohort,Disease specific,Hospital,Population-based,Rare disease collection | disease: Cardiac arrhythmia, unspecified | data categories: Biological samples,Medical records,National registries,Physiological/Biochemical measurements | materials: Buccal Swab,cDNA / mRNA,microRNA | omics: Proteomics | imaging: N | sex: Undifferentiated
To improve treatment of ventricular arrhythmias, research is conducted on many different levels: genetics, basic and clinical electrophysiology, national registries, human samples.
PREDICT2
Buccal Swab
Cardiac arrhythmia
microRNA
collection type: Longitudinal | disease: Obesity,Primary pulmonary hypertension,Disorders of lipoprotein metabolism and other lipidaemias - Pure hypercholesterolaemia,Mood [affective] disorders | data categories: Biological samples,Imaging data,Physiological/Biochemical measurements,Survey data | materials: Buccal Swab,Feaces,Peripheral blood cells,Plasma | omics: Metabolomics | imaging: Y | sex: Female,Male
Follow up of women (with obesity and unfulfilled wish for a child) and their children who participated in a preconception lifestyle intervention with focus on women's lifestyle, health and wellbeing and child growth, development, behavior and health (including cardiac ultrasound and MRI in children)
WOMB project: Women Offspring and iMproving lifestyle for Better cardiovascular health of Both
Disorders of lipoprotein metabolism and other lipidaemias - Pure hypercholesterolaemia
Mood affective disorders
WOMB
collection type: Cross-sectional,Disease specific,Hospital,Longitudinal | disease: Aortic aneurysm of unspecified site, without mention of rupture | data categories: Imaging data,Medical records,Physiological/Biochemical measurements | materials: Not available | omics: Not available | imaging: Y | sex: Female,Male
Aortic aneurysm is a life-threatening condition. When undetected, an aneurysm can grow and evolve into dissection or rupture. This RADAR-consortium will develop methods to detect aneurysms earlier. The techniques rely on multi-parametric MRI to evaluate aortic morphology, aortic vessel wall and blood flow, and computational fluid dynamics for blood pressure and wall shear stress.
RADAR: Earlier Recognition of Aortic Dissection and Aneurysm Rupture: The RADAR Study
Aortic aneurysm of unspecified site
RADAR
without mention of rupture
collection type: Disease specific,Rare disease collection | disease: Cerebrovascular diseases | data categories: Imaging data | materials: Not available | omics: Not available | imaging: Y | sex: Female,Male
Functional and structural MRI biomarkers of large and small vessel disease of the cerebral vasculature.
BRAIN@Risk
BRAIN Risk
Cerebrovascular diseases
Patiënten (kinderen en volwassenen) met een aangeboren hartafwijking, en kinderen (jonger dan 18 jaar) met een verworven hartafwijking.
De registratie Aangeboren hartafwijkingen, en verworven hartafwijkingen bij kinderen (AHVHK) omvat patiënten (zowel kind als volwassenen) met een aangeboren hartafwijking, en kinderen met een verworven hartafwijking. De patiënten binnen deze registratie worden geïncludeerd op basis van hun diagnose. Deze registratie omvat daarnaast ook alle hartkatheterisaties bij kinderen.
Aangeboren hartafwijkingen, en verworven hartafwijkingen bij kinderen registratie
ASD
TGA
Tetralogy of Fallot
VSD
collection type: Case-Control,Cohort,Disease specific,Hospital | disease: Angina pectoris,Unstable angina | data categories: Biological samples,Imaging data,Medical records | materials: Plasma | omics: Proteomics | imaging: Y | sex: Female,Male
Extracellular vesicle proteins in plasma subfractions are investigated to determine their ability for early diagnosis of stable and unstable angina using a blood test
EaRly diagnosis of Stable and Unstable Angina uSIng extracellular VEsicles
Unstable angina
pERSUASIVE
collection type: Disease specific,Hospital,Image collection,Longitudinal,Sample collection | disease: HFpEF | data categories: Biological samples,Imaging data,Medical records | materials: Plasma,Serum,Urine | imaging: Y | sex: Female,Male
In this phase 2 trial, we expect to obtain proof of concept for a beneficial effect of GGA on HFpEF. In HFpEF patients we will evaluate effects of GGA on signs and symptoms of HFpEF including echographic parameters of diastolic function, exercise tolerance, microvascular endothelial function and kidney function.
GeranylGeranylAcetone in Heart failure with preserved ejection fraction
GLADIATOR-HFpEF part of RECONNEXT
collection type: Case-Control,Cohort,Cross-sectional,Non-Human,Population-based,Sample collection | disease: Obesity,Type 2 diabetes mellitus | data categories: Biological samples,Imaging data,Physiological/Biochemical measurements,Survey data | materials: cDNA / mRNA,Cell lines,DNA,Peripheral blood cells,Plasma,RNA,Serum,Tissue, cryo preserved | omics: Metabolomics,Transcriptomics | imaging: Y | sex: Female,Male
this is not one project but a collection of cohort studies, human experimental words and much more
ENERGISE, Targeting energy metabolism to combat cardiovascular disease
Energise
collection type: Case-Control,Disease specific,Hospital | disease: Heart failure | data categories: Physiological/Biochemical measurements | materials: Not available | omics: Not available | imaging: N | sex: Female,Male
To invetigate if Low-dose Digoxin can effectively reduce cardiovascular mortality and recurrent HF hospitalizations, on top of the guideline-recommended therapies in HF patients with LVEF<50%
collection type: Hospital,Longitudinal,Sample collection | disease: Atrial fibrillation and atrial flutter, unspecified | data categories: Biological samples,Imaging data,Medical records,Physiological/Biochemical measurements,Survey data | materials: cDNA / mRNA,Plasma,RNA,Serum,Tissue, cryo preserved,Whole Blood | omics: Genomics,Proteomics,Transcriptomics | imaging: Y | sex: Female,Male
primary aim: study molecular mechanisms of AF by combining histology, biochemical analysis, and genome-wide RNA expression profiles. Secondary aim: study the incidence of AF during the first years after cardiac surgery in patients with or without a history of AF
Race V - Poaf
Atrial fibrillation and atrial flutter
collection type: Hospital,Image collection | data categories: Medical records,Other | materials: Not available | omics: Not available | imaging: Y | sex: Female,Male
This project explores continuous video monitoring of the cardiorespiratory status of a patient as an innovative unobtrusive method that could aid to reduce workload for the staff and better predict deterioration.
Video monitoring FOR early Signaling of adverse EvEnts
FORSEE
collection type: Cohort,Population-based | data categories: Medical records | materials: Not available | omics: Not available | imaging: N | sex: Female,Male
Rationale: Whilst patients with a tetralogy of Fallot have excellent survival in the present day, adverse events still occur regularly. However,risk stratification in these patients is not sufficient at this moment. Objective: The objective of this study is to report the long-term follow-up after ToF repair in a relatively large cohort and to determine predictors of long-term adverse outcomes. Study design: Retrospective observational study Study population: patients operated for tetralogy of Fallot in in the Netherlands Intervention (if applicable): n/a Main study parameters/endpoints: Cardiac related adverse events during the follow-up of tetralogy of Fallot
Outflow tract related aging with congenital heart defects: identifying causes and mechanisms of myocardial and large vessel wall adaptation, predictors for long term outcome and targets for improved treatment. Workpackage retroFallot study
collection type: Disease specific,Sample collection | disease: Subarachnoid haemorrhage,Intracerebral haemorrhage,Cerebral infarction,Stroke, not specified as haemorrhage or infarction,Transient cerebral ischaemic attack, unspecified | data categories: Biological samples,Imaging data,Medical records,Physiological/Biochemical measurements | materials: Plasma | omics: Other | imaging: Y | sex: Female,Male
To develop a liquid biopsy biomarker that can differentiate between the cause of stroke (ischemic and hemorrhagic stroke) in the acute phase, new technology will be developed and nanoparticles (small RNAs and extracellular vesicles) will be measured in plasma samples from patients with a supsicion of stroke.
Circulating Nanotraces to Identify the Cause of Stroke
CINTICS
Intracerebral haemorrhage
Stroke
Subarachnoid haemorrhage
Transient cerebral ischaemic attack
not specified as haemorrhage or infarction
Patiënten (kinderen en volwassenen) die een ablatie hebben ondergaan.
De Ablatie registratie omvat verschillende typen interventies gericht op het behandelen van verschillende hartritmestoornissen. Dit omvat onder andere His-ablaties, katheterablaties voor aandoeningen zoals atriale flutter, atriumfibrilleren, AV-nodale re-entry tachycardie (AVNRT), atriale tachycardie, ventriculaire extrasystolen (VES), en ventriculaire tachycardieën. Ook ablatie voor accessoire verbindingen en minimaal-invasieve chirurgische ablaties voor atriumfibrilleren, uitgevoerd via een thoracoscopische benadering, worden geregistreerd. Elke ablatie of poging tot ablatie wordt vastgelegd vanaf het moment van de eerste huidincisie. Diagnostische elektrofysiologische onderzoeken zonder geplande ablatie worden niet opgenomen in de registratie. Minimaal-invasieve chirurgische ablaties worden geregistreerd als ze niet gecombineerd worden met andere openhartchirurgie, zoals klep- of bypassoperaties. In het geval van gecombineerde procedures worden deze interventies opgenomen in de cardiochirurgieregistratie en niet in de ablatie-registratie.
Ablatie registratie
Electrophysiology
ablatie
ablation
collection type: Cohort,Cross-sectional,Hospital,Longitudinal | disease: Ischaemic heart diseases,Other forms of heart disease,Cerebrovascular diseases | data categories: Medical records | materials: Plasma,Serum,Whole Blood | omics: Not available | imaging: N | sex: Female,Male
Using big data analytics to develop flexible and improved cardiovascular risk prediction algorithms integrated and 'live' in routine clinical practice in order to improve cardiovascular prevention.
Improving prevention of cardiovascular disease: from proof of principle to implementation readiness of a live cardiovascular risk management dashboard in electronic health record in routine clinical practice
CVRM-IMPROVE
Other forms of heart disease
collection type: Longitudinal | disease: Chronic kidney disease | data categories: Medical records,National registries,Other,Survey data | materials: Not available | omics: Not available | imaging: N | sex: Female,Male
DOMESTICO or the Dutch nOcturnal and hoME dialysis Study To Improve Clinical Outcomes is a nationwide, combined retrospective and prospective, observational cohort study that included adult patients who started with a form of dialysis. The retrospective part of DOMESTICO (2012-2017, n = ± 1300 pts) focuses on clinical outcomes of home dialysis, in particular technique failure and hospitalization, compared to in-center hemodialysis, and on identifying modifiable factors. The prospective part of DOMESTICO (2017-2022, n = ± 2000 pts) focuses on 1. Determining the effects of home dialysis on various aspects of quality of life compared to in-center hemodialysis, measured by patient reported outcome measures (PROMs); and 2. Performing a cost-effectiveness analysis of the various forms of home dialysis compared to in-center hemodialysis, which should contribute to higher value-based health care (i.e. maximum value of patient care at the best costs).
DOMESTICO prospectief
Chronic kidney disease
DOMESTICO
collection type: Cohort,Disease specific,Longitudinal | data categories: Biological samples,Imaging data,Medical records,National registries,Physiological/Biochemical measurements | materials: Plasma | omics: Not available | imaging: Y | sex: Female,Male
Retrospective cohort study in patients with atrial switch operation, longitudinal Follow Up
collection type: Other | disease: Diastolic (congestive) heart failure | data categories: Imaging data | materials: Not available | omics: Not available | imaging: Y | sex: Female,Male
This project is focused on developing new MRI hardware and software for improved phenotyping of patients with HFpEF
Comprehensive, High definition Accelerated Non-invasive Cardiac MRI for Early diagnosis of patients with symptomatic heart disease
CHANCE
Diastolic congestive heart failure
The Amsterdam Dementia Cohort is an ongoing data collection including all patients who come to the Alzheimer Center Amsterdam for diagnostic work up and who consent to give all data, collected as part of the routine diagnostic work up, for research. The aim is to facilitate research into new and existing biomarkers in the broadest sense, to establish diagnostic, prognostic and theragnostic values and further insight into the pathogenesis of neurodegenerative dementias.
Amsterdam Dementia Cohort